Bausch Health Aktie [WKN DE: A2JQ1X / ISIN: CA0717341071]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Bausch Health

22.09.23		BHC DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action - BHC (PR Newswire)
03.09.23		ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Bausch Health Companies Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BHC (PR Newswire)
25.08.23		ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BHC (PR Newswire)
18.08.23		ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BHC (PR Newswire)
11.08.23		ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Bausch Health Companies Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BHC (PR Newswire)
04.08.23		ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BHC (PR Newswire)
28.07.23		ROSEN,TOP RANKED GLOBAL COUNSEL, Encourages Bausch Health Companies Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BHC (PR Newswire)
31.05.23		OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease (PR Newswire)
12.10.22		SALIX PHARMACEUTICALS RELEASES LIVER HEALTH ANNUAL TRENDS REPORT UNDERSCORING CHALLENGES IN CARING FOR GROWING CHRONIC LIVER DISEASE AND CIRRHOTIC PATIENT POPULATION (PR Newswire)
05.10.22		Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022 (PR Newswire)
03.10.22		SALIX PHARMACEUTICALS APPLAUDS IMPLEMENTATION OF K76.82 - A NEW ICD-10 CODE FOR HEPATIC ENCEPHALOPATHY (PR Newswire)
28.09.22		Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations (PR Newswire)
23.09.22		Bausch Health, Glenmark Specialty Say Health Canada Approves RYALTRIS (RTTNews)
14.09.22		Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations (PR Newswire)
09.09.22		Bausch Health Comments On Tentative FDA Approval Of Generic Version Of Antibiotic Xifaxan (RTTNews)
09.09.22		Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin (PR Newswire)
08.09.22		Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations (PR Newswire)
31.08.22		Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes (PR Newswire)
22.08.22		Bausch Health Continuing Process Toward Separating Bausch + Lomb (PR Newswire)
11.08.22		Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit (PR Newswire)
10.08.22		Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE) (PR Newswire)
09.08.22		BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS (PR Newswire)
28.07.22		Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation (PR Newswire)
28.07.22		Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9 (PR Newswire)
20.07.22		Bausch + Lomb Provides Leadership Update (PR Newswire)
13.07.22		Salix Announces 2022 Gastrointestinal Health Scholars Program Winners (PR Newswire)
23.06.22		Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors (PR Newswire)
21.06.22		Bausch Health Issues Form 8-K for 2022 Annual Meeting of Shareholders Presentation (PR Newswire)
20.06.22		Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2022 (PR Newswire)
16.06.22		Bausch Health Provides Update on Solta Medical (PR Newswire)
18.05.22		Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022 (PR Newswire)
11.05.22		Bausch Health Announces Participation In Upcoming Investor Conferences (PR Newswire)
10.05.22		Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions (PR Newswire)
10.05.22		Bausch Health Companies Inc. Announces First-Quarter 2022 Results (PR Newswire)
06.05.22		Bausch Health Announces Thomas J. Appio As Chief Executive Officer (PR Newswire)
06.05.22		Bausch + Lomb Prices IPO Of 35 Mln Shares At $18.00/shr (RTTNews)
06.05.22		Bausch + Lomb Corporation Announces Pricing of IPO (PR Newswire)
03.05.22		Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting (PR Newswire)
29.04.22		Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10 (PR Newswire)
28.04.22		Bausch + Lomb Corporation Announces Launch of IPO and Roadshow (PR Newswire)
28.04.22		Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation (PR Newswire)
28.04.22		Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting (PR Newswire)
27.04.22		Ortho Dermatologics Will Present Data at the 2022 Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference (PR Newswire)
25.04.22		Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting (PR Newswire)
21.04.22		Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs (PR Newswire)
20.04.22		Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health (PR Newswire)
18.04.22		Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting (PR Newswire)
04.04.22		HALF OF IBS PATIENTS SURVEYED REPORT IBS SYMPTOMS MORE CHALLENGING TO MANAGE IN THE PAST YEAR (PR Newswire)
29.03.22		Bausch Health Will Reduce Debt By $200 Million (PR Newswire)
28.03.22		Bausch + Lomb, Clearside Biomedical Launch XIPERE For Macular Edema Associated With Uveitis In U.S. (RTTNews)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Ripple auf dem Weg zu 100 US-Dollar in 2025?

Krypto-Rekorde voraus: Wall Street sieht Bitcoin bei 200.000 US-Dollar

EQS-Adhoc: STRABAG SE CEO Klemens Haselsteiner passed away completely unexpectedly

Ripple Kurs Prognose: 10 US-Dollar bis Ende des Jahres?

Diese Aktien empfehlen Experten zu kaufen

Trump ruft eigenen Krypto-Coin "$TRUMP" ins Leben - Kryptocoin auch für Melania

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	20.01.2025 15:02
Kaufwert:	EUR
	Hinzufügen Speichern